DDInter119 DDInter1387
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is marketed by Novartis under the brand name Farydak. Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market.
Panobinostat {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Panobinostat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Interferon beta-1a
Panobinostat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nepafenac
Panobinostat {u} may lead to a major life threatening interaction when taken with {v} Ivabradine
Panobinostat {u} may lead to a major life threatening interaction when taken with {v} Posaconazole
Panobinostat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Flurbiprofen
Panobinostat may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a
Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Nepafenac
Panobinostat may lead to a major life threatening interaction when taken with Ivabradine
Panobinostat may lead to a major life threatening interaction when taken with Posaconazole
Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Panobinostat may lead to a major life threatening interaction when taken with Flurbiprofen